LEXINGTON, Mass., May 10, 2018 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to
improve the lives of patients with immune-mediated diseases, announced the hiring of David
McMullin to the newly created position of Senior Vice President, Corporate Development and Strategy. Mr. McMullin
will be responsible for leading Aldeyra's commercial planning, corporate development, and business development efforts.
"We are pleased to welcome David to the Aldeyra team," commented Todd C. Brady, M.D., Ph.D.,
President and Chief Executive Officer of Aldeyra. "David's arrival highlights the evolution of Aldeyra towards a
pre-commercial enterprise, and we believe his leadership in the launch, management, and growth of multi-billion-dollar franchises
and divisions will add tremendous value to Aldeyra as we work towards our strategic goal of becoming a diversified company
focused on immunological disease."
Mr. McMullin brings extensive experience leading business development, strategic planning, commercial and operational
activities in the biopharmaceutical industry. Prior to joining Aldeyra, Mr. McMullin most recently served as the Group Vice
President of the $1.4 billion U.S. Internal Medicines franchise at Shire plc where he led sales,
marketing, and business operations for the U.S. rare disease and specialty products business. Previously, he was Vice
President of the Commercial Center of Excellence at Shire, responsible for commercial operations worldwide. Prior to
joining Shire, Mr. McMullin was the Vice President of Global Supply Chain and Strategy at Novartis Vaccines and Diagnostics (now
part of GlaxoSmithKline plc), where he led a successful operational turnaround followed by an asset swap divestiture between
Novartis AG and GlaxoSmithKline plc. He also held management positions in marketing, sales, and corporate strategy at
Novartis Pharmaceuticals and Novartis International, divisions of Novartis AG. Mr. McMullin received a Master of Business
Administration degree from Harvard University, and a Bachelor of Science degree from Brigham Young University.
About Aldeyra Therapeutics
Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated
diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye
disease and other forms of ocular inflammation. Aldeyra is leveraging its experience in ocular inflammation to develop other
product candidates for systemic inflammatory disease. None of Aldeyra's product candidates have been approved for sale in the
U.S. or elsewhere.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements regarding Aldeyra's strategy, future operations,
future, prospects, plans, and objectives. Aldeyra intends such forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as "may,"
"might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project,"
"target," "design," "estimate," "predict," "potential," "aim," "plan" or the negative of these terms, and similar expressions
intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve
risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have
any products that generate significant revenue. Important factors that could cause actual results to differ materially from those
reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement, completion and
reporting of Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra
and its development partners; updated or refined data based on Aldeyra's continuing review and quality control analysis of
clinical data, Aldeyra's ability to design clinical trials with protocols and endpoints acceptable to applicable regulatory
authorities, the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyra's
product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and
commercializing Aldeyra's product candidates; the size and growth of the potential markets for Aldeyra's product candidates and
the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and revenue, the sufficiency of Aldeyra's
cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra's product
candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract
or retain key personnel; Aldeyra's ability to establish and maintain development partnerships; Aldeyra's expectations regarding
federal, state and foreign regulatory requirements; regulatory developments in the United States and foreign countries;
Aldeyra's ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and
challenges in Aldeyra's business and the market in which it operates; and other factors that are described in the "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Aldeyra's Annual Report
on Form 10-K for the year ended December 31, 2017, which is on file with the Securities and Exchange Commission(SEC)
and available on the SEC's website at www.sec.gov. Additional factors may be described in those sections of
Aldeyra's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, which is expected to be filed with
the SEC in the second quarter of 2018. All of Aldeyra's development timelines may be subject to adjustment
depending on recruitment rate, regulatory review, preclinical and clinical results, and other factors that could delay the
initiation, completion or reporting of clinical trials.
In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable
factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ
materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra
undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future
events, or otherwise, except as required by law.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 Ext. 205
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-appoints-david-mcmullin-as-senior-vice-president-corporate-development-and-strategy-300646181.html
SOURCE Aldeyra Therapeutics, Inc.